Literature DB >> 25707573

The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling.

Jun Wei1, Archit K Ghosh, Haiyan Chu, Feng Fang, Monique E Hinchcliff, Jiucun Wang, Roberta Goncalves Marangoni, John Varga.   

Abstract

OBJECTIVE: Persistent fibroblast activation underlies skin fibrosis in systemic sclerosis (SSc), but the transcriptional and epigenetic mechanisms controlling this process are not well understood. In view of the potent influence of acetylation status governing tissue fibrosis, we undertook this study to investigate the expression of the antiaging deacetylase enzyme sirtuin 1 (SIRT1) in SSc and its effects on fibrotic responses in vitro and in vivo.
METHODS: Tissue expression of SIRTs was interrogated from publicly available genome-wide expression data sets and by immunohistochemistry. The effects of SIRT1 on modulating fibrotic responses, as well as the underlying mechanisms, were examined in human and mouse fibroblasts in culture and in an experimental fibrosis model in the mouse.
RESULTS: Analysis of transcriptome data revealed a selective reduction of SIRT1 messenger RNA (mRNA) levels in SSc skin biopsy samples as well as a negative correlation of SIRT1 mRNA with the skin score. Cellular SIRT1 levels were suppressed in normal fibroblasts exposed to hypoxia or platelet-derived growth factor and were constitutively down-regulated in SSc fibroblasts. Activation of SIRT1 attenuated fibrotic responses in skin fibroblasts and skin organ cultures, while genetic or pharmacologic inhibition of SIRT1 had profibrotic effects. The antifibrotic effects of SIRT1 were due in part to decreased expression and function of the acetyltransferase p300. In mice, experimentally induced skin fibrosis was accompanied by reduced SIRT1 expression in lesional tissue fibroblasts, and both fibrosis and loss of SIRT1 in these mice were mitigated by treatment with a SIRT1 activator.
CONCLUSION: SIRT1 has antifibrotic effects, and its reduced tissue expression in patients with SSc might have a direct causal role in progression of fibrosis. Pharmacologic modulation of SIRT1 in these patients therefore might represent a potential treatment strategy.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25707573      PMCID: PMC4518870          DOI: 10.1002/art.39061

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  52 in total

1.  Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis.

Authors:  Pawel Zerr; Katrin Palumbo-Zerr; Jingang Huang; Michal Tomcik; Barbora Sumova; Oliver Distler; Georg Schett; Jörg H W Distler
Journal:  Ann Rheum Dis       Date:  2014-09-01       Impact factor: 19.103

2.  Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3.

Authors:  Jinhua Li; Xinli Qu; Sharon D Ricardo; John F Bertram; David J Nikolic-Paterson
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  The type III histone deacetylase Sirt1 protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclaf1 promoter to inhibit T cell activation.

Authors:  Sinyi Kong; Seung-Jae Kim; Barry Sandal; Sang-Myeong Lee; Beixue Gao; Donna D Zhang; Deyu Fang
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

4.  Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy.

Authors:  M Sulaiman; M J Matta; N R Sunderesan; M P Gupta; M Periasamy; M Gupta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

5.  Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator.

Authors:  Asish K Ghosh; Swati Bhattacharyya; Jun Wei; Suyeon Kim; Yaacov Barak; Yasuji Mori; John Varga
Journal:  FASEB J       Date:  2009-04-24       Impact factor: 5.191

6.  sirt1-null mice develop an autoimmune-like condition.

Authors:  Jedon Sequeira; Gino Boily; Stephanie Bazinet; Sarah Saliba; Xiaohong He; Karen Jardine; Christopher Kennedy; William Staines; Colin Rousseaux; Rudi Mueller; Michael W McBurney
Journal:  Exp Cell Res       Date:  2008-07-23       Impact factor: 3.905

7.  Resveratrol induces mitochondrial biogenesis in endothelial cells.

Authors:  Anna Csiszar; Nazar Labinskyy; John T Pinto; Praveen Ballabh; Hanrui Zhang; Gyorgy Losonczy; Kevin Pearson; Rafael de Cabo; Pal Pacher; Cuihua Zhang; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

8.  A ChIP-cloning approach linking SIRT1 to transcriptional modificationof DNA targets.

Authors:  German Torres; Patrick D Frisella; Salman J Yousuf; Samina Sarwar; Lauren Baldinger; Sherry M Zakhary; Joerg R Leheste
Journal:  Biotechniques       Date:  2008-06       Impact factor: 1.993

9.  The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice.

Authors:  Jinping Zhang; Sang-Myeong Lee; Stephen Shannon; Beixue Gao; Weimin Chen; An Chen; Rohit Divekar; Michael W McBurney; Helen Braley-Mullen; Habib Zaghouani; Deyu Fang
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808

10.  CBP/p300-mediated acetylation of histone H3 on lysine 56.

Authors:  Chandrima Das; M Scott Lucia; Kirk C Hansen; Jessica K Tyler
Journal:  Nature       Date:  2009-03-08       Impact factor: 49.962

View more
  27 in total

Review 1.  Sirtuins in Skin and Skin Cancers.

Authors:  Liz Mariely Garcia-Peterson; Melissa Jean Wilking-Busch; Mary Ann Ndiaye; Christine Gaby Azer Philippe; Vijayasaradhi Setaluri; Nihal Ahmad
Journal:  Skin Pharmacol Physiol       Date:  2017-07-14       Impact factor: 3.479

Review 2.  Environmental risk factors of systemic sclerosis.

Authors:  Isabelle Marie; Jean-François Gehanno
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

3.  Sirtuin1 Protects against Systemic Sclerosis-related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes.

Authors:  Haiyan Chu; Shuai Jiang; Qingmei Liu; Yanyun Ma; Xiaoxia Zhu; Minrui Liang; Xiangguang Shi; Weifeng Ding; Xiaodong Zhou; Hejian Zou; Feng Qian; Philip W Shaul; Li Jin; Jiucun Wang
Journal:  Am J Respir Cell Mol Biol       Date:  2018-01       Impact factor: 6.914

Review 4.  Systemic sclerosis-associated fibrosis: an accelerated aging phenotype?

Authors:  Tracy R Luckhardt; Victor J Thannickal
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

Review 5.  Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma.

Authors:  Marta Bueno; Anna Papazoglou; Eleanor Valenzi; Mauricio Rojas; Robert Lafyatis; Ana L Mora
Journal:  Curr Rheumatol Rep       Date:  2020-06-19       Impact factor: 4.592

Review 6.  Unfolding the pathogenesis of scleroderma through genomics and epigenomics.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  J Autoimmun       Date:  2017-05-16       Impact factor: 7.094

Review 7.  Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.

Authors:  Pei-Suen Tsou
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

8.  Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts.

Authors:  Anne E Wyman; Zahid Noor; Rita Fishelevich; Virginia Lockatell; Nirav G Shah; Nevins W Todd; Sergei P Atamas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-04-06       Impact factor: 5.464

Review 9.  Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.

Authors:  Benjamin Korman
Journal:  Transl Res       Date:  2019-02-23       Impact factor: 7.012

Review 10.  Sirtuins and Accelerated Aging in Scleroderma.

Authors:  Anne E Wyman; Sergei P Atamas
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.